Expression and significance of stathmin1 in acute leukemia.
10.7534/j.issn.1009-2137.2013.05.004
- Author:
Jian-Ping XU
1
,
2
;
Jian-Da HU
;
Jing LI
;
Ting-Bo LIU
;
Min-Hui LIN
Author Information
1. Department of Laboratory Examination, College of Medical Technology and Engineering, Fujian Medical University, Fuzhou 350004, Fujian Province, China
2. Fujian Provincial Key Laboratory of Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian Province, China.
- Publication Type:Journal Article
- MeSH:
Acute Disease;
Adolescent;
Adult;
Case-Control Studies;
Humans;
Leukemia;
blood;
pathology;
Middle Aged;
Neoplasm, Residual;
blood;
diagnosis;
Stathmin;
blood;
Young Adult
- From:
Journal of Experimental Hematology
2013;21(5):1105-1110
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to investigate the expression of stathmin1 mRNA and stathmin1 protein in de novo patients with acute leukemia (AL), relapsed patients with AL and complete remission patients with AL, and its clinical significance. The expression of stathmin1 mRNA and stathmin1 protein in peripheral blood samples from 76 cases of AL and 25 healthy persons were examined by fluorescent quantitative PCR (FQ-PCR) and Western blot, respectively. The results showed that the stathmin1 protein expression could not be detected in healthy persons, only the low level of its mRNA could be observed in them. The stathmin1 mRNA expression level in de novo AL patients was higher than that in healthy persons (P < 0.05), the stathmin1 mRNA expression level in relapsed patients with AL was higher than that in de novo patients (P < 0.05), and there was no significant difference of stathmin1 mRNA expression between patients with AML and patients with ALL. The positive rate of stathmin1 protein expression in de novo patients with AL was 89%, while it obviously decreased or did not express in complete remission patients with AL. The stathmin1 protein expression in relapsed patients with AL did not display significant difference as compared with that in de novo patients (P > 0.05). There was no significant difference in stathmin1 protein expression between patients with AML and patients with ALL (P > 0.05). It is concluded that stathmin1 protein and mRNA are overexpressed in de novo patients and relapsed patients, and lowly expressed in complete remission patients. Therefore, the stathmin1 may be a new biological marker for evaluation of minimal residual disease.
